Editorial: Novel insights in pharmacogenetics of drug response in Parkinsons disease

Pharmacogenomics

Volumn 11, Issue 2, 2010, Pages 127-129

  Arbouw, Maurits El ^a,b   Guchelaar, Henk Jan ^c   Egberts, Toine Cg ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; MU OPIATE RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIPARKINSON AGENT; ENZYME;

BRADYKINESIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DYSKINESIA; EDITORIAL; GENE EXPRESSION REGULATION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; PARKINSON DISEASE; PHARMACOGENETICS; PREVALENCE; PROTEIN FUNCTION; PSYCHOSIS; RIGIDITY; SUBSTANTIA NIGRA PARS COMPACTA; TREMOR; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHYSIOLOGY;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; ENZYMES; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PHARMACOGENETICS;

EID: 77949617538     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.175     Document Type: Editorial

References (23)

1. Tanner CM, Goldman SM: Epidemiology of Parkinson's disease. Neurol. Clin. 14, 317-335 (1996).
2. Tanner CM, Ottman R, Goldman SM et al.: Parkinson disease in twins: an etiologic study. JAMA 281, 341-346 (1999).
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE; 056 Study Group: A fve-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342, 1484-1491 (2000).
4. Graham JM, Grunewald RA, Sagar HJ: Hallucinosis in idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63, 434-440 (1997).
5. Swen JJ, Huizinga TW, Gelderblom H et al.: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4, E209 (2007).
6. Arbouw ME, van Vugt JP, Egberts TC, Guchelaar HJ: Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 8, 159-176 (2007).
7. Paus S, Grunewald A, Klein C et al.: The DR D2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov. Disord. 23, 599-602 (2008).
8. Liu YZ, Tang BS, Yan XX et al.: Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur. J. Clin. Pharmacol. 65, 679-683 (2009).
9. Arbouw ME, Movig KL, Egberts TC et al.: Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur. J. Clin. Pharmacol. 65, 1245-1251 (2009).
10. Williams-Gray CH, Hampshire A, Barker RA, Owen AM: Attentional control in Parkinson's disease is dependent on COMT Val 158 Met genotype. Brain 131, 397-408 (2008)
11. Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT: Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 252, 130-134 (2007).
12. Swen JJ, Wilting I, de Goede AL et al.: Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008).
13. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
14. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R: Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 129, 1059-1069 (2006).
15. Jankovic J: Motor fuctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20(Suppl. 11), S11-S16 (2005).
16. Pechevis M, Clarke CE, Vieregge P et al.: Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. 12, 956-963 (2005).
17. Rascol O, Brooks DJ, Korczyn AD et al.: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. 21, 1844-1850 (2006).
18. Chase TN, Oh JD: Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91 (2000).
19. Conn PJ, Battaglia G, Marino MJ, Nicoletti F: Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6, 787-798 (2005).
20. Fumagalli F, Racagni G, Riva MA: Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J. 6, 95-104 (2006).
21. Moreau C, Destee A: A new perspective on brain derived neurotrophin factor polymorphism in L-dopa induced dyskinesia. J. Neurol. Neurosurg. Psychiatry 80, 129 (2009).
22. Foltynie T, Cheeran B, Williams-Gray CH et al.: BDNF Val66Met infuences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80, 141-144 (2009).
23. Kim SI, Voshol H, van OJ, Hastings TG, Cascio M, Glucksman MJ: Neuroproteomics: expression profling of the brain's proteomes in health and disease. Neurochem Res. 29, 1317-1331 (2004).